This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
25 Mar 2011

Cellerant Starts Leukaemia Drug Trial

The drug trial will assess the safety and tolerability of CLT-008 in the setting of chemotherapy-induced neutropenia.

Cellerant Therapeutics has launched a Phase I/II clinical trial of CLT-008 in patients receiving intensive post-remission chemotherapy for high-risk leukaemia or myelodysplasia. The open-label, multicentre, dose escalation trial will assess the safety and tolerability of CLT-008 in the setting of chemotherapy-induced neutropenia.

 

The trial will enroll approximately 30 evaluable patients with high-risk acute myelogenous leukaemia, acute lymphoblastic leukemia (ALL/AML), chronic myelogenous leukaemia (CML) or myelodysplasia (MDS).

 

The secondary objective includes efficacy-related endpoints such as time to neutrophil recovery, duration of severe neutropenia and thrombocytopenia, days of fever and incidenc

Related News